Pfizer (PFE) Cash from Operations (2009 - 2026)
Pfizer (PFE) posted quarterly Cash from Operations of 2615000000.0 for Q1 2026, up 11.99% year-over-year from 2335000000.0 in Q1 2025, and down 51.1% quarter-over-quarter from 5348000000.0 in Q4 2025.
Pfizer (PFE) Cash from Operations (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Cash from Operations for 18 consecutive years, with 2615000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 11.99% year-over-year to 2615000000.0; the TTM figure through Mar 2026 stood at 11984000000.0 (up 56.31% YoY), while the FY2025 annual figure was 11704000000.0, down 8.16% from the prior year.
- Cash from Operations eased to 2615000000.0 in Q1 2026 per PFE's latest filing, from 5348000000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8170000000.0 in Q3 2022 and bottomed at 1781000000.0 in Q2 2024.
- Historically, Cash from Operations has averaged 3046615384.62 across 5 years, with a median of 2615000000.0 in 2026.
- Annual changes were most pronounced in 2023 — Cash from Operations tumbled 114.79% — and 2025, when it surged 114.22%.
- Pfizer's Cash from Operations stood at 8170000000.0 in 2022, then sank by 35.86% to 5240000000.0 in 2023, then gained by 14.94% to 6023000000.0 in 2024, then slipped by 11.21% to 5348000000.0 in 2025, then plunged by 51.1% to 2615000000.0 in 2026.
- Business Quant data shows PFE's Cash from Operations at 2615000000.0 in Q1 2026, 5348000000.0 in Q4 2025, and 4603000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.29 Bn | 631.53 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.70 Bn | 463.14 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 374.92 Bn | 367.78 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 302.99 Bn | 295.30 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.63 Bn | 222.64 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 182.46 Bn | 179.28 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.59 Bn | 147.89 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.12 Bn | 101.95 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.21 Bn | 47.83 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 835.00 Mn |
| Jun 28, 2026 | 835.00 Mn |
| Mar 29, 2026 | 2.62 Bn |
| Mar 29, 2026 | 2.62 Bn |
| Dec 31, 2025 | 5.35 Bn |
| Dec 31, 2025 | 5.35 Bn |
| Sep 28, 2025 | 4.60 Bn |
| Sep 28, 2025 | 4.60 Bn |
| Jun 29, 2025 | -582.00 Mn |
| Jun 29, 2025 | -582.00 Mn |
| Mar 30, 2025 | 2.34 Bn |
| Mar 30, 2025 | 2.34 Bn |
| Sep 29, 2024 | 6.02 Bn |
| Sep 29, 2024 | 6.02 Bn |
| Jun 30, 2024 | -1.78 Bn |
| Jun 30, 2024 | -1.78 Bn |
| Mar 31, 2024 | 1.09 Bn |
| Mar 31, 2024 | 1.09 Bn |
| Dec 31, 2023 | 5.24 Bn |
| Dec 31, 2023 | 5.24 Bn |